Design of targeted B cell killing agents

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Stepanov, Alexey V ^a   Belogurov Jr , Alexey A ^a,b   Ponomarenko, Natalia A ^a   Stremovskiy, Oleg A ^a   Kozlov, Leonid V ^c   Bichucher, Anna M ^c   Dmitriev, Sergey E ^d   Smirnov, Ivan V ^a   Shamborant, Olga G ^a   Balabashin, Dmitry S ^d   Sashchenko, Lidia P ^b   Tonevitsky, Alexander G ^d   Friboulet, Alain ^e   Gabibov, Alexander G ^a,b   Deyev, Sergey M ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b INSTITUTE OF GENE BIOLOGY   (Russian Federation)

^c GN Gabrichevsky Moscow Research Institute of Epidemiology and Microbiology   (Russian Federation)

^d MOSCOW STATE UNIVERSITY   (Russian Federation)

^e UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BARNASE C MYC; ETA C MYC; FC C MYC; IMMUNOTOXIN; SLT C MYC; UNCLASSIFIED DRUG; AUTOANTIGEN; BACILLUS AMYLOLIQUEFACIENS RIBONUCLEASE; EPITOPE; MONOCLONAL ANTIBODY; MYC PROTEIN; RECOMBINANT PROTEIN; RIBONUCLEASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; GENETIC ENGINEERING; HYBRIDOMA; IN VITRO STUDY; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; SPLEEN CELL; ANIMAL; AUTOIMMUNE DISEASE; BAGG ALBINO MOUSE; CELL DEATH; CELL LINE; CHO CELL; CRICETULUS; CYTOLOGY; DRUG EFFECT; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; SPLEEN;

PSEUDOMONAS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIGENS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CELL DEATH; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; EPITOPES; HUMANS; HYBRIDOMAS; MICE; MICE, INBRED BALB C; PROTO-ONCOGENE PROTEINS C-MYC; RECOMBINANT PROTEINS; RIBONUCLEASES; SPLEEN;

EID: 79958154924     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020991     Document Type: Article

References (46)

1. Hikada M, Zouali M, (2010) Multistoried roles for B lymphocytes in autoimmunity. Nat Immunol 11: 1065-1068.
2. Belogurov A Jr, Kozyr A, Ponomarenko N, Gabibov A, (2009) Catalytic antibodies: balancing between Dr. Jekyll and Mr. Hyde. Bioessays 31: 1161-1171.
3. Jang YJ, Stollar BD, (2003) Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol Life Sci 60: 309-320.
4. Browning JL, (2006) B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov 5: 564-576.
5. Martin F, Chan AC, (2006) B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 24: 467-496.
6. Edwards JC, Cambridge G, (2006) B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 6: 394-403.
7. Leslie D, Lipsky P, Notkins AL, (2001) Autoantibodies as predictors of disease. J Clin Invest 108: 1417-1422.
8. Bizzaro N, (2008) The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin Rev Allergy Immunol 34: 326-331.
9. Belogurov AA Jr, Kurkova IN, Friboulet A, Thomas D, Misikov VK, et al. (2008) Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis. J Immunol 180: 1258-1267.
10. Tian J, Zekzer D, Hanssen L, Lu Y, Olcott A, et al. (2001) Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 167: 1081-1089.
11. Harris DP, Haynes L, Sayles PC, Duso DK, Eaton SM, et al. (2000) Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 1: 475-482.
12. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF, (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest 118: 3420-3430.
13. Mauri C, Ehrenstein MR, (2008) The 'short' history of regulatory B cells. Trends Immunol 29: 34-40.
14. Shimomura Y, Mizoguchi E, Sugimoto K, Kibe R, Benno Y, et al. (2008) Regulatory role of B-1 B cells in chronic colitis. Int Immunol 20: 729-737.
15. Chatenoud L, Bach JF, (2005) Regulatory T cells in the control of autoimmune diabetes: the case of the NOD mouse. Int Rev Immunol 24: 247-267.
16. Li Y, Chen F, Putt M, Koo YK, Madaio M, et al. (2008) B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol 181: 2961-2972.
17. Dorner T, Burmester GR, (2008) New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 20: 263-268.
18. Ostergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, et al. (2010) Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 62: 2227-2238.
19. Marriott JJ, O'Connor PW, (2010) Emerging therapies in relapsing-remitting multiple sclerosis. Rev Recent Clin Trials 5: 179-188.
20. Zhang L, French RR, Chan HT, O'Keefe TL, Cragg MS, et al. (1995) The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease. Ther Immunol 2: 191-202.
21. Grewal IS, Flavell RA, (1998) CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 16: 111-135.
22. Miga A, Masters S, Gonzalez M, Noelle RJ, (2000) The role of CD40-CD154 interactions in the regulation of cell mediated immunity. Immunol Invest 29: 111-114.
23. Ng LG, Mackay CR, Mackay F, (2005) The BAFF/APRIL system: life beyond B lymphocytes. Mol Immunol 42: 763-772.
24. Ouarzane M, Zouali M, (2007) Novel opportunities for therapeutic targeting in systemic autoimmune diseases. Methods Mol Biol 361: 285-297.
25. Cohen SB, (2006) Updates from B Cell Trials: Efficacy. J Rheumatol Suppl 77: 12-17.
26. Kaveri SV, Lacroix-Desmazes S, Bayry J, (2008) The antiinflammatory IgG. N Engl J Med 359: 307-309.
27. Dass S, Vital EM, Emery P, (2007) Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 56: 2715-2718.
28. Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF, (2007) Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis 13: 1365-1368.
29. Deyev SM, Waibel R, Lebedenko EN, Schubiger AP, Pluckthun A, (2003) Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol 21: 1486-1492.
30. Kurkova IN, Reshetnyak AV, Durova OM, Knorre VD, Tramontano A, et al. (2009) Antibodies-antidotes against organophosphorus compounds. Dokl Biochem Biophys 425: 94-97.
31. Vorob'ev II, Ponomarenko NA, Durova OM, Kozyr AV, Demin AV, et al. (2001) Structural-functional study of recombinant forms of onconase. Bioorg Khim 27: 257-264.
32. Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, et al. (2003) A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res 9: 2837-2848.
33. Dmitriev SE, Andreev DE, Adyanova ZV, Terenin IM, Shatskii IN, (2009) Efficient cap-dependent translation of mammalian mRNAs with long and highly structured 5′-untranslated regions in vitro and in vivo. Mol Biol (Mosk) 43: 108-113.
34. Andreev DE, Dmitriev SE, Terenin IM, Prassolov VS, Merrick WC, et al. (2009) Differential contribution of the m7G-cap to the 5′ end-dependent translation initiation of mammalian mRNAs. Nucleic Acids Res 37: 6135-6147.
35. Ivanov AE, Kozlov LV, Shojbonov BB, Zubov VP, Antonov VK, (1991) Inorganic supports coated with N-substituted polyacrylamides: application to biospecific chromatography of proteins. Biomed Chromatogr 5: 90-93.
36. Edelweiss E, Balandin TG, Ivanova JL, Lutsenko GV, Leonova OG, et al. (2008) Barnase as a new therapeutic agent triggering apoptosis in human cancer cells. PLoS One 3: e2434.
37. Tanimizu N, Ueno H, Hayashi R, (2002) Replacement of His12 or His119 of bovine pancreatic ribonuclease A with acidic amino acid residues for the modification of activity and stability. J Biosci Bioeng 94: 39-44.
38. Mossakowska DE, Nyberg K, Fersht AR, (1989) Kinetic characterization of the recombinant ribonuclease from Bacillus amyloliquefaciens (barnase) and investigation of key residues in catalysis by site-directed mutagenesis. Biochemistry 28: 3843-3850.
39. Zocher M, Baeuerle PA, Dreier T, Iglesias A, (2003) Specific depletion of autoreactive B lymphocytes by a recombinant fusion protein in vitro and in vivo. Int Immunol 15: 789-796.
40. Nachreiner T, Kampmeier F, Thepen T, Fischer R, Barth S, et al. (2008) Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. J Neuroimmunol 195: 28-35.
41. Brenner T, Steinberger I, Soffer D, Beraud E, Ben-Nun A, et al. (1999) A novel antigen-toxin chimeric protein: myelin basic protein-pseudomonas exotoxin (MBP-PE 40) for treatment of experimental autoimmune encephalomyelitis. Immunol Lett 68: 403-410.
42. Schreiber G, (2001) Methods for studying the interaction of barnase with its inhibitor barstar. Methods Mol Biol 160: 213-226.
43. Cheung MC, Revers L, Perampalam S, Wei X, Kiarash R, et al. (2010) An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo. Mol Cancer 9: 28.
44. Kreitman RJ, (2006) Immunotoxins for targeted cancer therapy. AAPS J 8: E532-551.
45. Engedal N, Skotland T, Torgersen ML, Sandvig K, (2010) Shiga toxin and its use in targeted cancer therapy and imaging. Microb Biotechnol 4: 32-46.
46. Wentworth P Jr, McDunn JE, Wentworth AD, Takeuchi C, Nieva J, et al. (2002) Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science 298: 2195-2199.